IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions - Wikidata - wikimedia - TriplyDB

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

http://www.wikidata.org/entity/Q28254218

about

Biomarkers of An Autoimmune Skin Disease--Psoriasis Cytokines in psoriasis Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN.Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance.Unprocessed Interleukin-36α Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1 Mutations in IL36RN are associated with geographic tongue.Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology.Cross-Disease Transcriptomics: Unique IL-17A Signaling in Psoriasis Lesions and an Autoimmune PBMC Signature Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab.Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist.IL-36γ has proinflammatory effects on human endothelial cells.IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis.Interleukin-36γ is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis.Epidermal cornification is preceded by the expression of a keratinocyte-specific set of pyroptosis-related genes.The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function.Autocrine and Paracrine Regulation of Keratinocyte Proliferation through a Novel Nrf2-IL-36γ Pathway.Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation.A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target.Tumour necrosis factor-α-inhibitor-induced neutrophilic folliculitis presenting with strong lesional expression of interleukin-36γ.Increased interleukin-36γ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sézary syndrome.Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa.Commensal microbiota modulate gene expression in the skin.RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature.Staphylococcus aureus Virulent PSMα Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-Dependent Skin Inflammation.A novel molecular disease classifier for psoriasis and eczema.Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines.IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment.Association analysis of psoriasis vulgaris and psoriatic arthritis with loss-of-function mutations in IL36RN in German patients.Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation.Detection of IL-36γ through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment

P2860

Q26781378-3BA631D4-6CBF-454D-AD62-B3F808AA795F Q28255491-088DE269-DDBC-4086-979D-61D44EA45193 Q33713754-60974E04-985F-40B2-B0AE-F1A5BA5C6085 Q34553191-32BD7376-5F41-4974-950B-C5A5E3499B4C Q35519210-D2B5D9B3-5256-4C04-80A5-472A9F4B1D96 Q35922976-F48F3DBF-B3D7-4631-A96D-AA03E217CCB1 Q36289222-37F6FAEE-8D8D-4F01-B9DF-B9CCA4AFC78C Q37601487-563E37DD-476C-43EA-BDEC-68EF15605B6D Q38831928-284DEBBC-A80F-4FCE-ABEE-71F3885EA45D Q38840151-E77D2DCE-A430-4CCC-9E1F-DD9ED6B09C25 Q40252612-4965E5E8-BE59-498A-92CC-EA6C4901176B Q40473700-51A96D45-3248-4DA0-AC54-EE04EFDA281F Q40526106-33C4A8DB-FFC9-43A4-8FD1-315C6CE1AB98 Q41035494-C6F086BA-4399-4708-8B6F-09252EE95523 Q41825896-88235BE9-59C8-452C-844B-F7DEAAD2AFB1 Q46242608-1D100769-46A7-42E0-A047-E37B6C54D283 Q46320645-76ED1220-239D-4B45-A8C3-291262BC42E5 Q46547722-01427339-3F0A-497D-AC09-00C3E4306C08 Q47358944-F5D650F8-33E2-4DC0-873C-87A10A2DC9D5 Q47657450-711D5BE3-93F0-46FD-862C-FFD3A4D48EA7 Q48208267-AA5851E9-4D2C-4D2C-89BE-7888CB85C29B Q48282383-8B763D33-19A5-4F83-88D2-587B08B3E2B6 Q48288323-448D990C-7C31-473D-ADA6-14554E0C18D5 Q48295806-1B8C24BB-0036-4DA3-896A-84770BA3709C Q49185989-756E6880-6FDA-4C6E-8F0B-EA39857182D1 Q50046027-E3B6A9AE-F991-42BB-AE75-12507F9C12F7 Q50094846-81B3CBA0-6601-49BC-BD10-880C03EC3244 Q50643263-3F3E3E0A-574C-4EDD-9AB4-29074C8E44B6 Q51072843-F1276505-4953-4150-9DFF-1A74697E769F Q52802857-F71D68DB-7D2C-46F1-9005-D60687D0D140 Q52886990-636AA334-2323-4720-873F-118E35D0038D Q53778589-7702FF9F-85F2-48FB-98EE-68297C2F37EB Q55111930-0A01B269-69A6-49A3-9EA4-75306BAB763A Q56591790-296A67D1-3509-4CBE-9948-91ABCF345611 Q58093804-5C02DE7C-6929-47C6-A627-F2EA7BF7CCD4

P2860

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

http://www.wikidata.org/entity/Q28254218

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@ast

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@en

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@nl

type

label

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@ast

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@en

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@nl

prefLabel

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@ast

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@en

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@nl

P1154

Q28254218-3794D93C-C04E-4605-BFD6-724EEEAF9FEF

P1433

Q28254218-5AF07F48-1D8D-4F30-8C46-49B4F5C52C99

P1476

Q28254218-8333F001-033F-4D49-B1B2-4C683348EBD3

P2093

Q28254218-040D75A0-7C1E-45CE-B383-0DF80BDA6342

Q28254218-0C496AA8-FAD9-43FD-83CB-28CD6C9DB8A4

Q28254218-16B3F089-3786-4760-AB2A-3AAACE51CDB6

Q28254218-23CDB8AA-6C7F-4EC9-9902-8BD96FEC748F

Q28254218-58D26F99-3ABC-4DE6-AA22-627EFCF2BE05

Q28254218-7DAC2961-50EB-4475-8D72-87339EB10BA5

Q28254218-8267C494-E0CA-41FC-BF27-EDB6F5BA3729

Q28254218-CF06B1BE-C2B6-4382-8B61-618F5E800715

Q28254218-EE0C2A3A-CFC2-4A02-B654-B900234D821F

Q28254218-F170731D-3889-454A-AB45-17559162A3AF

P2888

Q28254218-9D538764-02DE-467D-9A86-866949145598

P304

Q28254218-EE5651CA-88CA-47A7-9C18-197F3216D1F6

P31

Q28254218-4F44D7F9-46C2-4932-BA00-1BC1734BA64B

P3181

Q28254218-03490DC9-9718-4C8C-9C98-9B0C8EFBD975

P356

Q28254218-8A9084CB-AB0F-448C-B7E5-D908AE6B5E63

P407

Q28254218-2220E002-9EF4-4A0D-9A85-EFAD6210C67D

P433

Q28254218-AB74C624-E729-4512-B91D-DD624B3CEB29

P478

Q28254218-A722EB31-2CDD-40AD-BD11-E3D6C408A218

P50

Q28254218-0838FD8F-112B-4DB6-B912-9C999CF77BCF

P5530

Q28254218-BD63BF23-D659-4182-8EB2-3A8380F26E91

P577

Q28254218-EBCD0EF5-C310-4091-9B69-8819D8FCC366

P6179

Q28254218-22CD9356-8179-4F60-9C5E-6834FCB581EB

P6409

Q28254218-7411AEDB-A1C2-441D-B072-086AAC6665D6

P698

Q28254218-240FC5F2-5494-45BE-82F5-6E1F4491E588

P921

Q28254218-D4771EED-BBDE-4978-9794-3396005CB7F8

P953

Q28254218-ED56604D-B43D-4D91-9384-199013CE836B

P3181

P356

P1154

2-s2.0-84925381286

http://www.w3.org/2001/XMLSchema#string

P1433

Journal of Investigative Dermatology

P1476

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

@en

P2093

Andreas Bosio

http://www.w3.org/2001/XMLSchema#string

Angelo Massimiliano D'Erme

http://www.w3.org/2001/XMLSchema#string

Bettina Peters

http://www.w3.org/2001/XMLSchema#string

Dagmar Wilsmann-Theis

http://www.w3.org/2001/XMLSchema#string

Julia Wagenpfeil

http://www.w3.org/2001/XMLSchema#string

Michael Hölzel

http://www.w3.org/2001/XMLSchema#string

Miriam Wittmann

http://www.w3.org/2001/XMLSchema#string

Sandra Ferring-Schmitt

http://www.w3.org/2001/XMLSchema#string

Sonja Sternberg

http://www.w3.org/2001/XMLSchema#string

Thomas Bieber

http://www.w3.org/2001/XMLSchema#string

P2888

P304

1025-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2152728

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/JID.2014.532

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

P5530

3094620

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033323389

http://www.w3.org/2001/XMLSchema#string

P6409

82299961

http://www.w3.org/2001/XMLSchema#string

P698

25525775

http://www.w3.org/2001/XMLSchema#string

P921

P953